Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KESTREL: Brolucizumab versus Aflibercept in Diabetic Macular Edema
2017-004742-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2018
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brolucizumab in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in BCVA at Week 52. Started Apr 2018; status: completed.
02
Drugs
brolucizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2017-004742-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004742-23.